Vertex Pharmaceuticals Incorporated — FY 2018 Form 10-K
Reporting period: Year ended December 31, 2018. Although the request references 2018 Q4, this is an annual report; quarterly figures are identified where relevant. Amounts are in U.S. dollars.
Business context
Vertex develops and commercializes medicines primarily for cystic fibrosis (CF), with three marketed products: SYMDEKO/SYMKEVI, ORKAMBI and KALYDECO. These medicines were approved to treat approximately half of the estimated 75,000 CF patients in North America, Europe and Australia. The company is also developing treatments for pain, sickle cell disease, beta-thalassemia, alpha-1 antitrypsin deficiency and other diseases.
Key financial metrics
| Metric | FY 2018 | FY 2017 |
|---|---|---|
| Total revenue | $3.048 billion | $2.489 billion |
| Net product revenue | $3.038 billion | $2.165 billion |
| Operating income | $635.2 million | $123.2 million |
| Net income attributable to Vertex | $2.097 billion | $263.5 million |
| Diluted earnings per share | $8.09 | $1.04 |
| Cash flow from operations | $1.270 billion | $844.9 million |
| Cash, cash equivalents and marketable securities | $3.168 billion | $2.089 billion |
| Working capital | $2.723 billion | $1.842 billion |
Revenue increased 22%; net product revenue increased 40%. Cost of sales was $409.5 million, or approximately 13.5% of CF product revenue (approximately 86.5% product gross margin on that basis). Operating margin was approximately 20.8%. Net income and net margin were substantially boosted by a non-cash $1.56 billion tax benefit from releasing valuation allowances; without that benefit, reported earnings would have been markedly lower.
Operating cash flow was $1.270 billion. Capital expenditures were $95.5 million, implying approximate operating cash flow less capital expenditures of $1.175 billion. The company reported no outstanding borrowings under its $500 million revolving credit facility at year-end. It had $561.9 million of long-term construction financing lease obligations and approximately $29.5 million of capital lease obligations; these lease obligations are not equivalent to funded revolving debt.
Material changes versus prior period
- CF product revenue rose by $872.8 million, principally reflecting SYMDEKO’s U.S. launch, label expansions and increased patient access in some international markets.
- SYMDEKO/SYMKEVI generated $768.7 million in 2018, compared with no reported product revenue in 2017. ORKAMBI revenue declined 4.4% to $1.262 billion, partly as U.S. patients switched to SYMDEKO. KALYDECO revenue rose to $1.008 billion from $844.6 million.
- Total revenue growth was partly offset by the absence of the $230 million Merck upfront collaboration payment recognized in 2017; collaborative and royalty revenue fell to $9.3 million from $323.2 million.
- Combined research and development and SG&A expenses increased 8% to $1.97 billion. Total costs and expenses rose only 2%, in part because 2017 included a $255.3 million impairment charge, compared with a $29 million impairment in 2018.
- Cash, cash equivalents and marketable securities increased 52%. The company repurchased $350 million of shares during 2018, with $150 million remaining under its authorized repurchase program at year-end.
Outlook, commentary and risks
- Management expected CF product revenue to increase in 2019, driven in part by a full year of SYMDEKO sales. Further growth depended on reimbursement agreements abroad and potential approval of a triple-combination CF regimen.
- After positive Phase 3 results for VX-659 in late 2018, Vertex expected VX-445 Phase 3 data in the first quarter of 2019, selection of a regimen and an FDA NDA submission no later than mid-2019. These were expectations, not assured outcomes.
- The triple-combination program is strategically important but carries clinical, regulatory, launch, reimbursement and market-acceptance risks. Potential switching from existing Vertex therapies could also displace some current product revenue.
- International pricing remains a key uncertainty. At year-end, $354.4 million collected for ORKAMBI through French early-access programs was recorded as an accrual; Vertex expected to return some amount after final French pricing was established. The final amount and timing were not clear in the filing.
- Net income included the one-time, non-cash $1.56 billion tax benefit following release of most valuation allowances. Management expected to begin recording a significant income tax provision in 2019 as deferred tax assets were used. The balance sheet included $1.500 billion of deferred tax assets.
- Unusual development items included discontinuation of VX-210 following a data monitoring board recommendation and a related $29 million impairment charge. Vertex also cited heavy reliance on CF products, competition, payer pricing pressure, clinical and regulatory uncertainty, and dependence on third-party manufacturing, including suppliers in China.
- Management stated that existing cash, investments and expected CF product cash flows were sufficient to fund operations for at least the next twelve months. Lease commitments and potential collaboration milestones remain additional funding requirements.
Important facts for investors to verify
- Whether subsequent clinical data, regulatory review and commercialization support the expected triple-combination filing and launch timetable.
- Progress and final terms of ORKAMBI reimbursement discussions in France and the U.K., including the ultimate refund due from the French early-access receipts.
- Whether SYMDEKO/SYMKEVI growth can offset continued ORKAMBI switching and sustain overall CF revenue growth.
- The realization and use of deferred tax assets, and the resulting cash and reported tax burden after the exceptional 2018 tax benefit.
- Cash generation, lease obligations, share repurchases and any changes in the company’s dependence on CF products or third-party supply.